Suppr超能文献

利尿剂的作用部位及机制。

Site and mechanism of the action of diuretics.

作者信息

Odlind B

出版信息

Acta Pharmacol Toxicol (Copenh). 1984;54 Suppl 1:5-15. doi: 10.1111/j.1600-0773.1984.tb03625.x.

Abstract

The mechanism of action of diuretics can be established by studying the molecular mechanism of action, the site of action within the nephron, and the relationship between the pharmacokinetics of the diuretic and its effect. The molecular mechanism of action is known for diuretic agents such as acetazolamide (carbonic anhydrase), theophylline (phosphodiesterase), digitalis glucosides (Na-K-ATPase), spironolactone (aldosterone antagonism) and dopamine (specific receptors?). The "receptor" for the clinically most important diuretics, i.e. loop diuretics, thiazides, and other potassium-sparing diuretics is, however, unknown. It appears from recent studies of the ion transport in the diluting segment that there probably is a sodium-chloride co-transport in this segment and that loop diuretics specifically inhibit the active chloride transport. The main site of diuretic action is well established for the different groups of diuretics: carbonic anhydrase inhibitors act on the proximal tubulus, loop diuretics on the diluting segment, thiazides on the cortical diluting segment/distal tubulus, and potassium-sparing agents on distal tubulus/collecting ducts. Moreover, some diuretics have additional tubular sites of action. It is also important to realize that other effects of diuretics, e.g. inhibition of the tubuloglomerular feedback mechanism or renal and extra-renal hemodynamic effects, can modify the tubular diuretic effect. Finally, the renal handling of diuretics is of importance to the diuretic effect by determining the concentration of the drug at the "receptor" sit (s). It is emphasized that knowledge of the different aspects of the mechanisms of action of diuretics is a prerequisite for rational use of diuretics, clinically as well as experimentally.

摘要

利尿剂的作用机制可以通过研究其分子作用机制、在肾单位内的作用部位以及利尿剂的药代动力学与其效应之间的关系来确定。利尿剂如乙酰唑胺(碳酸酐酶)、茶碱(磷酸二酯酶)、洋地黄苷(钠钾ATP酶)、螺内酯(醛固酮拮抗作用)和多巴胺(特异性受体?)的分子作用机制是已知的。然而,临床上最重要的利尿剂,即袢利尿剂、噻嗪类利尿剂和其他保钾利尿剂的“受体”尚不清楚。从最近对稀释段离子转运的研究来看,该段可能存在氯化钠共转运,而袢利尿剂可特异性抑制氯离子的主动转运。不同类型利尿剂的主要作用部位已明确:碳酸酐酶抑制剂作用于近端小管,袢利尿剂作用于稀释段,噻嗪类利尿剂作用于皮质稀释段/远端小管,保钾利尿剂作用于远端小管/集合管。此外,一些利尿剂还有其他肾小管作用部位。还必须认识到,利尿剂的其他效应,如对肾小管-肾小球反馈机制的抑制或肾脏及肾外血流动力学效应,可改变肾小管的利尿作用。最后,利尿剂的肾脏处理方式对于通过确定药物在“受体”部位的浓度来影响利尿效果很重要。需要强调的是,了解利尿剂作用机制的不同方面是临床和实验中合理使用利尿剂的前提条件。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验